Pleus, Stefan
Jendrike, Nina
Baumstark, Annette
Mende, Jochen
Wehrstedt, Stephanie http://orcid.org/0009-0000-4586-4660
Haug, Cornelia
Freckmann, Guido
Funding for this research was provided by:
i-SENS Inc., Korea
Article History
Received: 18 October 2023
Accepted: 29 November 2023
First Online: 15 December 2023
Declarations
:
: Guido Freckmann is general manager and medical director of the Institute for Diabetes Technology (Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany), which carries out clinical studies e.g., with medical devices for diabetes therapy on its own initiative and on behalf of various companies. G.F./IfDT have received research support, speakers’ honoraria or consulting fees in the last three years from Abbott, Ascensia, Berlin Chemie, Boydsense, Dexcom, Lilly, Metronom, Medtronic, Menarini, MySugr, Novo Nordisk, PharmaSens, Roche, Sanofi, Terumo. Stefan Pleus, Nina Jendrike, Annette Baumstark, Jochen Mende, Stephanie Wehrstedt and Cornelia Haug are employees of IfDT.
: The study was approved by the responsible ethics committee prior to subject recruitment and subjects gave written informed consent prior to any study procedures. This study was exempted from approval by the competent authority by national law. All local regulations and requirements of Good Clinical Practice were followed and the study was performed following the Declaration of Helsinki.